Mantle cell lymphoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
BFR, then allo HSCT Variant #01 Partial | — | R 133 406 | — | — | — | ~1 | ~R 133 406 indirect | — |
Lenalidomide and Rituximab (R2) Variant #08 | — | R 106 523 | 28d | — | ~8.5 mo | ~13 | ~R 141 371 PFS proxy · indirect | 1 |
Fludarabine, Busulfan, Cyclophosphamide, then allo HSCT Variant #01 Partial | — | R 19 131 | — | — | — | ~1 | ~R 19 131 indirect | — |
V-BEAM Variant #01 Partial | — | R 11 108 | — | — | — | ~1 | ~R 11 108 indirect | — |
4 of 4 regimens shown